Colgate-Palmolive India
NSE: COLPALPersonal Care
Share price
₹1,735.70
-1.23% close of 8 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 6 Oct 2026, the close above is 8 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
69
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹46,864 Cr
P/E ratio
34.8
P/B ratio
29.8
ROCE
108.0%
ROE
26.6%
Dividend yield
2.6%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 3.8% over the past year, and 8.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 29.9% to 30.6% over the last four years.
Whether it grew faster than its sector
It grew 8.3% a year against a sector median of 9.9% — 1.6 percentage points slower.
Room to re-rate, or risk of de-rating
At 34.8× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 35.9×, across 5 companies. It is against its own five-year median of 43.6×, the 0th percentile of its own range.
Whether growth justifies the valuation
Priced at 4.3 times its growth rate, on earnings growth of 8%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Colgate-Palmolive India — this one | 8%/yr | 34.8× | ₹4.3 |
| Godrej Consumer Products | 5%/yr | 42.5× | ₹8.5 |
| Dabur India | 4%/yr | 33.6× | ₹8.4 |
| Cupid Limited | — | 348.8× | — |
| Gillette India Limited | 31%/yr | 35.9× | ₹1.2 |
| Procter & Gamble Hygiene and Health Care Limited | 14%/yr | 27.8× | ₹2.0 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Personal Care), it ranks 2 of 10 on returns, 8 of 10 on growth, 2 of 10 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 108% on capital, ahead of 80% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹7201 crore of cash from the business, spent ₹342 crore on plant and equipment, and returned ₹6466 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 112 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being paid 25 days before it paid its own suppliers to paid 59 days before it paid its own suppliers.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
9 of 9 checks clear · 100%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Sales of 1,603 crore rupees and net profit of 343 crore rupees, with the small price rise promised in May still to reach shops.
Announced 29 Jul 2026 · Standalone
Revenue
₹1,603 Cr
Net profit
₹343 Cr
Net margin
21.4%
EPS
₹12.61
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹46,864 Cr
- Prev close
- ₹1,735.70
- 52w High
- ₹2,330
- 52w Low
- ₹1,716
- Enterprise value
- ₹47,547 Cr
- Beta
- 0.8
- Price CAGR 1y
- -19.0%
- Price CAGR 3y
- -3.0%
- Price CAGR 5y
- 1.0%
- Price CAGR 10y
- 6.0%
Ratios
- Return on assets
- 38.9%
- PEG ratio
- 4.3
- P/E ratio
- 34.8
- P/B ratio
- 29.8
- EV / EBITDA
- 25.4
- Industry P/E
- 34.7
- ROCE
- 108.0%
- ROCE 5y average
- 96.2%
- ROE
- 26.6%
- Debt / Equity
- 0.0
- Interest coverage
- 447.0
- Dividend yield
- 2.6%
- ROE 3y average
- 79.0%
- ROE last year
- 83.0%
Annual P&L
- Annual revenue
- ₹6,035 Cr
- Annual profit
- ₹1,325 Cr
- Operating margin
- 31.0%
- Net profit margin
- 22.0%
- EBITDA margin
- 31.0%
- Sales growth 3y
- 4.9%
- Sales growth 5y
- 4.5%
- Profit growth 3y
- 8.0%
- Profit growth 5y
- 5.0%
- EPS
- ₹48.7
- Sales growth TTM
- 4.0%
- Profit growth TTM
- -2.0%
- Dividend payout
- 119.0%
Quarter P&L
- Sales latest quarter
- ₹1,603 Cr
- Profit latest quarter
- ₹343 Cr
- YoY quarterly sales growth
- 11.8%
- YoY quarterly profit growth
- 6.9%
- OPM latest quarter
- 30.1%
Balance Sheet
- Book Value
- ₹58.7
- Face Value
- ₹1.0
- Total debt
- ₹47 Cr
- Total cash
- ₹1,469 Cr
- Borrowings
- ₹47 Cr
- Reserves / Equity
- 57.7
Cash Flow
- Operating cash flow
- ₹1,806 Cr
- Free cash flow
- ₹1,730 Cr
- FCF yield
- 3.7%
- Net cash flow
- ₹758 Cr
Shareholding
- Promoter holding
- 51.0%
- FII holding
- 13.6%
- DII holding
- 15.5%
- Public holding
- 19.6%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Godrej Consumer | 872.50 | 43.0 | 89,251 | 2.29 | 504.5 | 10.6 | 4,225.5 | 15.4 | 18.8 |
| Dabur India | 388.90 | 34.8 | 69,108 | 2.12 | 586.2 | 15.0 | 3,764.4 | 10.6 | 20.3 |
| Colgate-Palmoliv | 1,809.40 | 36.2 | 49,506 | 2.65 | 343.1 | 7.8 | 1,603.3 | 11.8 | 108.0 |
| Cupid | 324.20 | 317.4 | 43,608 | 0.00 | 44.2 | 194.0 | 157.0 | 142.5 | 33.9 |
| Gillette India | 7,057.00 | 34.4 | 22,962 | 2.55 | 159.5 | 9.4 | 783.0 | 10.8 | 90.7 |
| P & G Hygiene | 6,865.00 | 28.2 | 22,296 | 3.35 | 126.3 | -34.3 | 891.5 | -4.9 | 157.2 |
| Emami | 384.00 | 22.2 | 16,790 | 2.60 | 138.9 | -16.4 | 1,039.2 | 14.9 | 28.1 |
| Median | 454.40 | 38.6 | 16,197 | 0.34 | 90.5 | 15.0 | 756.0 | 15.4 | 30.2 |
Competes with: Bajaj Consumer Care Limited, Cupid Limited, Dabur India, Emami Limited, Gillette India Limited, Godrej Consumer Products, Honasa Consumer Limited, JHS Svendgaard Laboratories Limited, Procter & Gamble Hygiene and Health Care Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,324 | 1,471 | 1,396 | 1,490 | 1,497 | 1,619 | 1,462 | 1,463 | 1,434 | 1,520 | 1,486 | 1,595 | 1,603 |
| Expenses | 906 | 989 | 927 | 958 | 988 | 1,122 | 1,007 | 964 | 981 | 1,054 | 1,044 | 1,086 | 1,120 |
| Material Cost | 386 | 346 | 394 | 372 | 427 | 433 | |||||||
| Change in Inventories | -22 | 60 | -14 | -0.08 | -23 | -41 | |||||||
| Purchases of Stock-in-Trade | 65 | 40 | 84 | 74 | 77 | 90 | |||||||
| Employee Cost | 107 | 118 | 118 | 118 | 121 | 129 | |||||||
| Other Expenses | 427 | 418 | 472 | 480 | 484 | 510 | |||||||
| Operating Profit | 418 | 482 | 468 | 532 | 508 | 497 | 454 | 498 | 453 | 465 | 442 | 510 | 483 |
| OPM % | 32 | 33 | 34 | 36 | 34 | 31 | 31 | 34 | 32 | 31 | 30 | 32 | 30 |
| Other Income | -5 | 21 | 18 | 23 | 23 | 76 | 20 | 19 | 18 | 15 | 31 | 0 | 19 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -8.39 | -17 | -3.34 | |||||||
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 44 | 44 | 41 | 42 | 42 | 42 | 41 | 38 | 38 | 37 | 36 | 35 | 39 |
| Profit before tax | 369 | 458 | 443 | 511 | 489 | 530 | 433 | 478 | 432 | 442 | 436 | 474 | 462 |
| Tax % | 26 | 26 | 26 | 26 | 26 | 26 | 25 | 26 | 26 | 26 | 26 | 25 | 26 |
| Net Profit | 274 | 340 | 330 | 380 | 364 | 395 | 323 | 355 | 321 | 328 | 324 | 353 | 343 |
| EPS in Rs | 10 | 13 | 12 | 14 | 13 | 15 | 12 | 13 | 12 | 12 | 12 | 13 | 13 |
| Diluted EPS in Rs | 13 | 12 | 12 | 12 | 13 | 13 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,982 | 3,868 | 3,982 | 4,188 | 4,462 | 4,525 | 4,841 | 5,100 | 5,226 | 5,680 | 6,040 | 6,035 | 6,204 |
| Expenses | 3,159 | 2,929 | 3,038 | 3,074 | 3,226 | 3,323 | 3,331 | 3,534 | 3,679 | 3,779 | 4,082 | 4,165 | 4,304 |
| Material Cost | 1,579 | 1,538 | |||||||||||
| Change in Inventories | -71 | 23 | |||||||||||
| Purchases of Stock-in-Trade | 310 | 276 | |||||||||||
| Employee Cost | 447 | 475 | |||||||||||
| Other Expenses | 1,817 | 1,853 | |||||||||||
| Operating Profit | 823 | 940 | 944 | 1,114 | 1,236 | 1,202 | 1,510 | 1,566 | 1,547 | 1,901 | 1,958 | 1,870 | 1,900 |
| OPM % | 21 | 24 | 24 | 27 | 28 | 27 | 31 | 31 | 30 | 33 | 32 | 31 | 31 |
| Other Income | 32 | 7 | 41 | 26 | 68 | 49 | 30 | 26 | 42 | 57 | 139 | 64 | 66 |
| Exceptional items (within Other Income) | 0 | -25 | |||||||||||
| Interest | 0 | 0 | 0 | 0 | 2 | 10 | 7 | 6 | 5 | 5 | 4 | 3.79 | 4 |
| Depreciation | 75 | 111 | 133 | 157 | 159 | 198 | 182 | 177 | 175 | 172 | 163 | 146 | 148 |
| Profit before tax | 780 | 835 | 851 | 983 | 1,143 | 1,043 | 1,350 | 1,409 | 1,410 | 1,781 | 1,930 | 1,784 | 1,814 |
| Tax % | 28 | 30 | 32 | 32 | 32 | 22 | 23 | 23 | 26 | 26 | 26 | 26 | |
| Net Profit | 559 | 581 | 577 | 673 | 776 | 816 | 1,035 | 1,078 | 1,047 | 1,324 | 1,437 | 1,325 | 1,348 |
| EPS in Rs | 21 | 21 | 21 | 25 | 29 | 30 | 38 | 40 | 39 | 49 | 53 | 49 | 50 |
| Diluted EPS in Rs | 53 | 49 | |||||||||||
| Dividend Payout % | 58 | 47 | 47 | 97 | 81 | 93 | 100 | 101 | 101 | 119 | 97 | 119 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 5%
- 5 years
- 5%
- 3 years
- 5%
- TTM
- 4%
Compounded profit growth
- 10 years
- 8%
- 5 years
- 5%
- 3 years
- 8%
- TTM
- -2%
Stock price CAGR
- 10 years
- 6%
- 5 years
- 1%
- 3 years
- -3%
- 1 year
- -19%
Return on equity
- 10 years
- 66%
- 5 years
- 75%
- 3 years
- 79%
- Last year
- 83%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 757 | 1,004 | 1,247 | 1,497 | 1,420 | 1,567 | 1,139 | 1,707 | 1,689 | 1,847 | 1,637 | 1,557 |
| Borrowings | 0 | 0 | 0 | 0 | 83 | 102 | 91 | 83 | 69 | 72 | 61 | 47 |
| Other Liabilities | 932 | 972 | 1,037 | 1,039 | 1,097 | 908 | 1,637 | 1,084 | 1,098 | 1,250 | 1,293 | 1,777 |
| Total Liabilities | 1,702 | 2,003 | 2,311 | 2,564 | 2,626 | 2,604 | 2,894 | 2,902 | 2,883 | 3,197 | 3,019 | 3,408 |
| Fixed Assets | 782 | 1,008 | 1,108 | 1,146 | 1,191 | 1,123 | 1,065 | 963 | 862 | 794 | 776 | 718 |
| CWIP | 141 | 78 | 167 | 159 | 199 | 190 | 145 | 122 | 114 | 110 | 38 | 27 |
| Investments | 37 | 31 | 31 | 31 | 31 | 19 | 19 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 742 | 885 | 1,005 | 1,228 | 1,206 | 1,272 | 1,666 | 1,817 | 1,907 | 2,292 | 2,204 | 2,663 |
| Total Assets | 1,702 | 2,003 | 2,311 | 2,564 | 2,626 | 2,604 | 2,894 | 2,902 | 2,883 | 3,197 | 3,019 | 3,408 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 638 | 689 | 688 | 694 | 983 | 930 | 784 | 1,626 | 1,176 | 1,199 | 1,394 | 1,806 |
| Cash from Investing Activity | -272 | -237 | -342 | -207 | -96 | -19 | 71 | -108 | -8 | 79 | 56 | 374 |
| Cash from Financing Activity | -385 | -391 | -341 | -380 | -815 | -891 | -956 | -1,091 | -1,087 | -1,195 | -1,671 | -1,422 |
| Net Cash Flow | -18 | 61 | 5 | 107 | 73 | 20 | -101 | 427 | 82 | 83 | -221 | 758 |
| Free Cash Flow | 339 | 417 | 367 | 485 | 879 | 869 | 727 | 1,576 | 1,107 | 1,123 | 1,323 | 1,730 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6 | 10 | 12 | 18 | 17 | 11 | 9 | 16 | 11 | 11 | 14 | 13 |
| Inventory Days | 63 | 72 | 72 | 56 | 58 | 69 | 79 | 78 | 68 | 63 | 76 | 75 |
| Days Payable | 128 | 136 | 148 | 152 | 144 | 142 | 179 | 169 | 155 | 187 | 185 | 275 |
| Cash Conversion Cycle | -59 | -55 | -63 | -79 | -68 | -63 | -91 | -75 | -76 | -113 | -95 | -188 |
| Working Capital Days | -40 | -43 | -39 | -33 | -36 | -23 | -84 | -25 | -32 | -46 | -37 | -59 |
| ROCE % | 114 | 96 | 74 | 71 | 73 | 65 | 92 | 92 | 79 | 97 | 105 | 108 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
2,65,15,817inr
2026-03-31
News
News and filings about Colgate-Palmolive India. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Carton board / paper packaging
- Palm oil derivatives / oleochemicals (surfactants, soap base)
- Plastic packaging (laminate tubes, HDPE/PP bottles & caps)
- Silica, calcium carbonate, fluoride & flavours
- Sorbitol (corn-derived) & humectants
Products made by
Depends on the price of
- Crude Oil Brent
- Palm Oil
- corn
- paper_pulp
Buys from
- Aarti Surfactants Limited · Surfactants for oral and personal care; CARE Dec-2025 preferred-supplier list
- Bajaj Healthcare Limited · Chlorhexidine base/digluconate (oral-care antiseptic)
- Blue Jet Healthcare Limited · Saccharin and its salts (high-intensity sweetener)
- EPL Limited · laminated/extruded oral-care tubes and specialty packaging
- Galaxy Surfactants Limited · surfactants and specialty ingredients for oral/personal care (founding contract-manufactur…
- Gem Aromatics Limited · specialty ingredients (essential oils, aroma chemicals and derivatives)
- Gulshan Polyols Limited · Sorbitol (toothpaste excipient)
- Huhtamaki India Limited · Tube laminates & flexible packaging (oral care)
- JK Paper Limited · folding cartons / packaging boards via packaging business
- Shree Vasu Logistics Limited · CFA, warehousing & 3PL logistics services
- TCPL Packaging Limited · Folding carton packaging (Colgate)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Fast Moving Consumer Goods
- Industry
- Personal Care
- Classification
- Fast Moving Consumer Goods › Personal Care
- ISIN
- INE259A01022
Plants
- Baddi plant · Baddi, Himachal Pradesh
- Kundaim plant · Kundaim, Goa
- Sanand plant
- Sri City plant · Sri City / Satyavedu, Andhra Pradesh
News impact
Big market events that reach Colgate-Palmolive India, and how the effect spreads.
1 Oct, 10:47 IST · Market event · high impact
Cupid shares hit fresh 52-week high as firm raises FY27 revenue, profit guidance again; multibagger stock skyrockets 617% in a year
Cupid raised FY27 targets to Rs 800 crore sales and Rs 250 crore profit on booming demand, lifting its own shares to a new high while rival consumer-goods makers gain nothing.
Who it hits first
- Cupid raised its FY27 targets for the second time in two weeks, now guiding Rs 800 crore revenue and Rs 250 crore net profit.
- Shares hit a fresh 52-week high, extending a 617% one-year run on strong home and export demand.
- No other company's earnings change: the raise covers Cupid's own orders only.
Who may gain
- Cupid shareholders, who see higher expected earnings and a fresh 52-week high
- Cupid distributors and export partners, if higher volumes flow through their channels
- No peer beneficiary: rival consumer-goods makers gain no sales from Cupid's own targets
Along the supply chain
Downstream
Distributors and export agents handling Cupid's products move higher volumes as the raised targets turn into shipments.
Upstream
Mild upstream pull: if Cupid makes more goods, its raw-material and packaging suppliers see slightly bigger orders.
Where demand moves
Business
Real product demand: buyers at home and abroad are ordering more of Cupid's goods, which is why its targets rose twice in two weeks.
Capital
Growth money chases the raise, bidding Cupid to a 52-week high; peers see no spillover inflows since their earnings are untouched.
How it spreads across sectors
Fast Moving Consumer Goods
Neutral: large consumer-goods makers share no shelf or tender with Cupid's niche, so no sales spill over.
Healthcare
Positive but narrow: one small company's beat lifts sentiment without changing hospital, lab or pharma demand.
When it plays out
Immediate
Cupid extends gains over 1-7 days as the raise sinks in; peers drift with the market.
Medium term
Over 1-6 months Cupid must convert guidance into quarterly numbers; any miss would unwind the premium fast.
Short term
Over 1-4 weeks Cupid consolidates near highs unless buyers keep chasing; profit-booking risk grows after 617%.
29 Sept, 17:34 IST · Market event · high impact
Cupid shares end 10% higher ahead of Nifty Smallcap 250 inclusion tomorrow. How much inflows can it see?
Cupid joins the Nifty Smallcap 250 tomorrow, forcing index funds to buy its shares, which helps Cupid holders but leaves rival personal-care makers untouched.
Who it hits first
- Cupid Limited, a small maker of personal-care and contraceptive goods, jumped 10% to Rs 291 on news that it joins the Nifty Smallcap 250 index from September 30.
- Joining the index means mutual funds and exchange-traded funds that copy that index (called passive funds) must buy Cupid shares, creating a one-off wave of forced buying.
- The stock has already surged 250% in six months, and strong June-quarter results plus higher FY27 guidance give buyers a growth story beyond the index news.
- No factory, order, or sales change is involved — this is purely a money-flow event, not a business event.
Who may gain
- Cupid's existing shareholders, who gain as forced index buying pushes the share price up.
- Cupid Limited itself, which gets more visibility and easier future fundraising as an index stock.
- Short-term traders who bought before the announcement and can sell into the passive demand.
Along the supply chain
Downstream
No direct supply-chain link downstream — distributors and retailers see no change in product flow from a stock-market event.
Upstream
No direct supply-chain link upstream — index inclusion does not change Cupid's raw-material or packaging orders.
Where demand moves
Business
No change in business demand — shops do not order more Cupid products because the stock joined an index; sales depend on the June-quarter momentum and guidance, not the listing.
Capital
Positive capital demand for Cupid only — passive funds that copy the Nifty Smallcap 250 must buy the stock around September 30, and active traders front-running that bid amplified the 10% pre-move.
How it spreads across sectors
Fast Moving Consumer Goods
Neutral for peers — Godrej Consumer, Dabur, Emami, Colgate and other personal-care makers get no order or money-flow spillover from Cupid's inclusion.
Healthcare
Negligible — a single-stock index-flow event with no change in healthcare demand, pricing, or regulation.
When it plays out
Immediate
September 30 inclusion day: forced passive buying, high volume, and a choppy price as pre-positioned traders sell into the index bid.
Medium term
1–6 months: index status stops mattering; only earnings delivery against the raised guidance and the stretched valuation decide the path.
Short term
1–4 weeks: tracking settles, the index premium fades, and the price drifts on profit-taking versus the FY27 guidance story.
29 Sept, 10:17 IST · Market event · high impact
Honasa Consumer Share Price Falls Over 3% On Block Deal Buzz
Early investors plan to sell up to 89 lakh Honasa shares in a block deal, so Honasa shares fell over 3%, hurting current holders while block buyers may get a discount and rivals see no change.
Who it hits first
- Honasa Consumer, which sells Mamaearth beauty and baby-care products, fell over 3% after news that early backers may sell up to 89 lakh shares in one block trade.
- Peak XV Partners, Sequoia Capital Global Growth Fund III and Redwood Trust are the likely sellers, cashing out part of their early stake.
- A big sale like this adds many shares for sale at once, so the price dips until new buyers absorb the block.
Who may gain
- Block-deal buyers, who may pick up Honasa shares at a discount to the market price
- Short-term traders who sold early on the buzz and can buy back lower after the sale
- Patient buyers who want Honasa for its brands and get a cheaper entry on the dip
Along the supply chain
Downstream
No downstream change — Nykaa, the beauty retailer that sells Honasa products, sees the same shopper demand; only Honasa's share price moves.
Upstream
No upstream change — software and order-service providers to Honasa see no order change when investors sell shares.
Where demand moves
Business
No change in shop demand — people buy the same Mamaearth creams and shampoos; only share ownership changes hands.
Capital
Selling pressure on Honasa shares — up to 89 lakh shares offered in the block must find new buyers, so the price slips until the block clears.
How it spreads across sectors
Fast Moving Consumer Goods
No real ripple — a single-company share sale does not change soap, cream or shampoo sales for Dabur, Godrej Consumer, Emami or Colgate.
When it plays out
Immediate
In 1-7 days, Honasa stays weak as the 89-lakh-share block hangs over the price and clears.
Medium term
In 1-6 months, price follows business — Mamaearth growth and profits matter, not the old investor exit.
Short term
In 1-4 weeks, shares steady once the block finds buyers and focus returns to sales and margins.
12 Sept, 04:23 IST · Market event · low impact
Colgate-Palmolive weighs sale of mass-market personal care brands in $1 billion-plus deal
Colgate's global parent may sell $1 billion of soap brands to focus on premium products — its Indian arm, which sells mostly toothpaste, is barely affected.
Who it hits first
- Colgate India: no direct earnings impact; sentiment mildly positive on parent focus
Who may gain
- Parent shareholders on portfolio premiumization; potential brand buyers
Along the supply chain
Downstream
Indian distributors and retailers see no portfolio change from this global move.
Upstream
No change — Indian sourcing and manufacturing footprint untouched by a US brand sale.
Where demand moves
Business
No demand shifts — Indian toothpaste volumes and pricing continue on domestic drivers.
Capital
FMCG investors note the premiumization theme; no meaningful rotation into COLPAL on this headline.
How it spreads across sectors
Fast Moving Consumer Goods
neutral — global portfolio move with no India earnings read-through
When it plays out
Immediate
COLPAL flat to +1% on sentiment
Medium term
Non-event unless India assets enter the sale perimeter
Short term
Deal contours clarify; no India impact expected
29 Aug, 04:36 IST · Market event · medium impact
FSSAI proposes mandatory red-hexagon front-of-pack warning labels on packaged foods high in sugar, salt or fat
India's food regulator wants a red warning box on the front of any packet that is high in sugar, salt or fat, the way cigarette packs carry warnings - a threat to biscuit, snack and soft-drink sales if it becomes law, though it is still only a proposal.
Who it hits first
- Packaged food makers in the high-sugar, high-salt and high-fat categories - biscuits, snacks, confectionery, instant noodles, soft drinks, dairy desserts - would have to carry a red hexagon warning on the front of pack.
- Britannia, Nestle India, Varun Beverages and Hatsun Agro are the most directly exposed listed names.
- This is still a draft open to consultation, not a final order, so nothing changes for at least several quarters.
Who may gain
- Companies already positioned in health, low-sugar and nutrition variants, which gain a visible shelf advantage over marked competitors.
- Specialty ingredient and sweetener suppliers, as reformulation demand rises across the industry.
- Food testing, certification and labelling-compliance service providers.
Along the supply chain
Downstream
Downstream, modern retailers and quick-commerce platforms would have to display the warnings in listings too, and past international experience is that marked products lose shelf prominence. Small kirana retail is less affected because the warning is on the pack rather than the shelf.
Upstream
Reformulation is an upstream event: it pulls demand towards sweetener, fibre, salt-replacement and fat-substitute suppliers and towards flavour houses that can rescue taste after a recipe cut. Packaging and label printers face a mandatory redesign of every affected pack, which is a one-time volume of work for them.
Where demand moves
Business
A warning label does not remove demand for snacking, it redirects it - shoppers shift towards unmarked variants, smaller pack sizes, and fresh or unpackaged alternatives, which is a quiet transfer from organised packaged food towards local unbranded producers who are outside the labelling net. Inside the industry, demand shifts towards reformulated and 'no-warning' variants, pulling orders towards ingredient suppliers who can cut sugar, salt and fat without ruining taste.
Capital
Investors mark down the pure-play high-sugar and high-fat names - biscuits, soft drinks, ice cream - and rotate towards diversified consumer companies where food is a minority of revenue, such as Hindustan Unilever, and towards health-positioned portfolios. Because this is a draft rule, that rotation is slow and reverses quickly if the thresholds are diluted in consultation.
How it spreads across sectors
Consumer Services
Quick-service restaurants face parallel pressure for menu labelling.
Fast Moving Consumer Goods
Volume risk in high-sugar, high-salt and high-fat categories, plus reformulation and repackaging cost.
Healthcare
A public-health-positive measure that supports the diabetes and obesity prevention agenda.
codex additions
When it plays out
Immediate
Minimal. It is a draft, and markets have seen labelling proposals stall before.
Medium term
If it is notified with strict thresholds, expect a genuine reformulation cycle across Indian packaged food over one to two years, with volume pressure concentrated in biscuits, confectionery and sugary drinks.
Short term
Watch the consultation submissions and whether industry succeeds in softening the thresholds - that, not the proposal itself, determines the impact.
Other sectors it reaches
- {"causal_chain":"Mandatory front-of-pack warning labels would require artwork redesign, plate changes, inventory write-offs and new packaging runs across packaged food SKUs, supporting demand for flexible packaging, cartons and label converters.","direction":"positive","example_tickers":["UFLEX","EPL","TCPLPACK"],"magnitude":"medium","notes":"Benefit depends on implementation timeline and whether brands can exhaust old packaging inventory.","sector":"Packaging \u0026 Label Printing","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Packaged food companies may reformulate to reduce sugar, salt or fat thresholds, increasing demand for sweeteners, emulsifiers, starches, flavor systems and functional ingredients.","direction":"positive","example_tickers":["TATACHEM","GODREJIND","JUBLINGREA"],"magnitude":"medium","notes":"Reformulation demand is plausible but category-specific; margins may improve for higher-value ingredient suppliers.","sector":"Specialty Ingredients \u0026 Food Additives","time_horizon":"1_to_6_months"}
- {"causal_chain":"Warning labels on high-sugar foods and beverages could pressure sugar-heavy packaged categories, while also accelerating substitution toward alternative sweeteners and low-calorie formulations.","direction":"mixed","example_tickers":["BALRAMCHIN","TRIVENI","DWARKESH"],"magnitude":"small","notes":"Negative for refined sugar demand from packaged foods, partly offset if companies diversify into ethanol or specialty sweeteners.","sector":"Sugar \u0026 Sweeteners","time_horizon":"1_to_6_months"}
- {"causal_chain":"Prominent warning labels can alter shelf conversion, search filters and merchandising, shifting demand from HFSS packaged foods toward healthier substitutes and private-label reformulations.","direction":"mixed","example_tickers":["DMART","TRENT","NYKAA"],"magnitude":"small","notes":"Retailers may see mix shifts rather than demand destruction; platforms with health-focused discovery could benefit.","sector":"Organized Food Retail \u0026 Grocery Platforms","time_horizon":"1_to_6_months"}
- {"causal_chain":"Packaged food brands facing label-driven perception risk may increase spending on repositioning, health claims, packaging communication and campaigns for reformulated products.","direction":"positive","example_tickers":["ZEEL","SUNTV","NAZARA"],"magnitude":"small","notes":"Ad budgets could initially be cautious, but brand repair and relaunch cycles create second-order demand.","sector":"Media, Advertising \u0026 Brand Consulting","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Dairy desserts, flavored milk and sweetened yogurts may face warning-label risk, while plain dairy, protein-led and low-sugar variants could gain relative share.","direction":"mixed","example_tickers":["HATSUN","HERITGFOOD","DODLA"],"magnitude":"medium","notes":"Impact is more relevant for value-added sweetened portfolios than commodity milk.","sector":"Dairy \u0026 Value-Added Milk Products","time_horizon":"1_to_6_months"}
- {"causal_chain":"Threshold compliance would require nutrient profiling, lab testing, documentation and supplier audits before label claims and warning status are finalized.","direction":"positive","example_tickers":["SYNGENE","THYROCARE","KRSNAA"],"magnitude":"small","notes":"Pure-play listed food-testing exposure is limited; benefit may accrue to diversified diagnostics, CRO and certification-adjacent businesses.","sector":"Food Testing, Inspection \u0026 Certification","time_horizon":"immediate"}
- {"causal_chain":"Label redesign, new cartons, new sleeves and compliance-driven packaging changes can lift demand for paperboard, printing inks and packaging substrates.","direction":"positive","example_tickers":["JKPAPER","TNPL","SHREYANS"],"magnitude":"small","notes":"Likely a temporary volume pull-forward unless rules trigger repeated SKU-level redesigns.","sector":"Paper, Inks \u0026 Printing Consumables","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"If reformulation reduces sugar, palm oil or salt intensity and increases grains, millets, nuts, proteins or natural ingredients, upstream crop demand mix may shift.","direction":"mixed","example_tickers":["KAVVERITEL","KSCL","AVANTIFEED"],"magnitude":"small","notes":"Listed exposure is indirect and diffuse; strongest link is through ingredient substitution rather than immediate volume change.","sector":"Agricultural Inputs \u0026 Commodities","time_horizon":"1_to_6_months"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 1 Jun 2026 | interim | ₹24 |
|---|---|---|
| 3 Nov 2025 | interim | ₹24 |
| 28 May 2025 | interim | ₹27 |
| 4 Nov 2024 | interim | ₹24 |
| 6 Nov 2023 | interim | ₹22 |
| 19 May 2023 | interim | ₹21 |
| 31 Oct 2022 | interim | ₹18 |
| 5 May 2022 | interim | ₹21 |
Splits, bonuses & buybacks
- daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-264 Jul 2026
- Earnings call · Q4FY2622 May 2026
- Earnings call · Q4FY2522 May 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.